OctoPlus signs drug delivery agreement with Novartis

Published: 1-Jul-2010
Research & Development Finance

PolyActive technology to be used to develop controlled release formulation of undisclosed compound


OctoPlus, a Dutch drug delivery company, has signed an agreement with Novartis relating to the use of OctoPlus' controlled release technology.

Under the contract, OctoPlus will develop, up to in vivo feasibility, a controlled release formulation of an undisclosed compound using its PolyActive proprietary drug delivery technology. Novartis will fully reimburse OctoPlus for its activities under the agreement. Further financial terms of the agreement were not disclosed.

Simon Sturge, ceo of OctoPlus, said: ‘I am delighted to see our technology being evaluated by such a prestigious company as Novartis. This along with the recent data on Locteron in more than 175 patients continues to build the strong support behind our PolyActive controlled release technology and our capabilities in this area.’

  • Companies:
  • OctoPlus
  • Novartis
See more

You may also like

Research & Development

Novartis' Leqvio demonstrates LDL cholesterol management potential in Phase III trial

Read more
The siRNA can significantly reduce the levels of LDL cholesterol in the blood, reducing the risk of ASCVD in patients

Trending Articles

  1. Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to the business and the APAC region
  2. Novo Holdings completes acquisition of Catalent Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
  3. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets
  4. Thermo Fisher Scientific reveals MagMax Sequential DNA/RNA Kit to advance blood cancer research The kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications
  5. Newcells Biotech raises additional funding from investors Newcells Biotech, a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, has raised a further £1.2m from existing investors Mercia Ventures, Northstar Ventures and North East Finance

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Research & Development

Novartis' Leqvio demonstrates LDL cholesterol management potential in Phase III trial

The siRNA can significantly reduce the levels of LDL cholesterol in the blood, reducing the risk of ASCVD in patients
Finance

Calypso enters into agreement to be acquired by Novartis

The acquisition of Calypso gives Novartis full rights to CALY-002, a pipeline-in-a-drug with potential in dermatology, gastrointestinal and rheumatology indications
Research & Development

Intellegens secures $2m to support research of oligonucleotide therapeutic manufacture

In collaboration with CPI, Intellegens has secured a grant from Innovate UK to fund a two year project to augment technology that will assist productivity and yields of oligonucleotide therapeutic manufacture
Manufacturing

Novartis completes acquisition of precision medicine developer Chinook

Novartis has announced the acquisition of a US-based biopharmaceutical company focused on the discovery of precision medicines for kidney diseases named Chinook Therapeutics
Manufacturing

MIT researchers to lead a new centre for continuous mRNA manufacturing

Faculty at the MIT are embarking upon a three-year research programme to design the world's first fully integrated, continuous mRNA manufacturing platform
Drug Delivery

Novartis publishes data on multiple sclerosis treatment

Data showed the sustained efficacy of continuous Kesimpta (ofatumumab) treatment over five years in patients with relapsing forms of multiple sclerosis (RMS)
Research & Development

Novartis and MMV move to Phase III study to treat uncomplicated malaria

As the world faces emerging resistance to current malaria treatments, new medicines are needed to continue the fight toward elimination
Subscribe now